background: The presence of chromosomal abnormalities could have a negative impact for human embryonic stem cell (hESC) applications both in regenerative medicine and in research. A biomarker that allows the identification of chromosomal abnormalities induced in hESC in culture before they take over the culture would represent an important tool for defining optimal culture conditions for hESC. Here we investigate the expression of CD30, reported to be a biomarker of hESCs with abnormal karyotype, in undifferentiated and spontaneously differentiated hESC.
Introduction
Despite the increased number of human embryonic stem cell (hESC) lines, as exemplified by the more than 500 lines registered in the European hESC Registry (www.hescreg.eu), no standard conditions that are optimal or generically applicable to all hESC lines have been established for their derivation and culture (Allegrucci and Young, 2007) . The different culture conditions between laboratories, such as different origins of feeder layers, culture media composition, cell density and passage method, may induce the selection of cells with growth advantage in a specific culture system, with direct effect on the hESC characteristics. In this regard, cells with both gross and submicroscopic (i.e. below the detection limit of conventional G-banding) chromosomal abnormalities appear most likely as a consequence of progressive adaptation to the culture conditions (Baker et al., 2007) and consequently take over the culture, with negative impact for hESC applications in research and regenerative medicine.
At present, various techniques are used for cytogenetic analysis of hESC, from classical methods that analyse chromosomes at microscopic level [G-banding, fluorescence in-situ hybridization (FISH), chromosome painting] to the molecular methods that allow a better resolution by analysing the DNA [metaphase or array based comparative genomic hybridization (CGH), and single-nucleotide polymorphism arrays] (Josephson, 2007) . Nevertheless, these techniques are either labour intensive, costly or may not detect aberrant subpopulations within a low-grade mosaic cell line. Therefore, a biomarker that allows for the early identification of abnormal hESC before they take over the culture would be extremely useful not only for high throughput quality control, but also as a tool for finding optimal culture conditions for hESC. Herszfeld et al. (2006) identified a surface antigen, CD30, which appeared to mark karyotypically abnormal, but not normal, hESC cultures. A more recent report (Thomson et al., 2008) found that CD30 was expressed by hESC with both normal and abnormal karyotypes, but was up-regulated in the latter. CD30 is a member of the tumour necrosis factor receptor superfamily, originally identified as a surface marker for malignant cells in Hodgkin's disease (Schwab et al., 1982) and strongly expressed in embryonal carcinomas (Pera et al., 1997) .
Considering the contradicting results regarding CD30 expression in normal and abnormal hESC, we were interested in evaluating the CD30 expression on hESC derived and cultured in our laboratory conditions [co-culture with mouse embryonic fibroblasts (MEF), media supplemented with KO-SR and mechanical passaging] in order to evaluate the possibility of using CD30 expression as a tool for early detection of chromosomal abnormality. More specifically, we have investigated the expression of CD30 in two different passages of the same lines and searched for a possible correlation with the chromosomal abnormalities (gross and submicroscopic) reported in our cultures (Spits et al., 2008) . The evaluation was performed at the level of gene expression by RT-PCR and relative quantitative real-time RT-PCR (Rq RT-PCR) and at the protein level by immunocytochemistry and fluorescence-activated cell sorting (FACS).
Materials and Methods

Cell cultures
hESC (lines VUB01, VUB02 and VUB04_CF) were derived, cultured and characterized as previously reported . Briefly, the cells were maintained in 10% CO 2 at 378C in hESC medium [KODMEM (Invitrogen, Auckland, NZ) containing 20% KO -SR (KNOCKOUT TM SR, Serum Replacement for ES cells; Invitrogen), 2 mM Glutamine (Invitrogen), 1% non-essential amino-acids (NEAA, Invitrogen), 1 mM b-mercaptoethanol (Sigma Aldrich, St. Louis, MO, USA), 4 ng/ml basic fibroblast growth factor (Invitrogen) and 1% Pen/Strep (Invitrogen)] on mytomycin-inactivated CF1 MEF and were passaged by mechanical dissociation every 5 -6 days.
For some experiments, hESC were cultured on MEF in hESC medium in which KO-SR was replaced with foetal bovine serum (FBS, Hyclone, Logan, UT, USA), or on matrigel TM (hESC-qualified Matrix; BD Bioscience; Bedford, MA, USA) in commercially available mTeSR medium as described by the provider (StemCell Technologies Inc., Vancouver, Canada).
For the early differentiation studies, clumps of hESC colonies (VUB02 and VUB04_CF) were replated on matrigel TM -coated 4-well dishes and cultured further in hESC medium. For Rq RT-PCR analysis, RNA samples were collected at day 2 and 4 and compared with undifferentiated hESC. For immunostaining experiments, cells were fixed in 70% ethanol at day 1, 2 and 4.
Human neonatal dermal fibroblasts (HF) (P16; CC2509, Cambrex; www.cambrex.com) were maintained in 5% CO 2 at 378C in MEF medium [Dulbecco's modified Eagle's medium (DMEM, Invitrogen) medium supplemented with 10% foetal calf serum (Invitrogen), 2 mM Glutamine and 1% NEAA (Invitrogen)], and passaged when they reached confluence.
RT-PCR
Total RNA was extracted from predominantly undifferentiated hESC and from a primary culture of bone-marrow derived human mesenchymal stem cells, isolated as previously reported (Pittenger et al., 1999 ; negative control sample), using the RNeasy Mini Kit (Qiagen, Hilden, Germany). First-strand complementary DNA (cDNA) Synthesis Kit (GEHealthcare, Buckinghamshire, UK) with the NotI-d(T)18 primer was used to reverse transcribe the RNA. A DNAse treatment (RNase-Free DNase Set; Qiagen) was performed in all the samples. Primers for the canonical transcript of CD30 were: forward 5 0 -CTGTGTCCCCTACCCAATCT-3 0 (start nucleotide position 1517, Gene Bank accession number M83554) and the reverse primer 5 0 -CACTGAGAGCATGACATCGC-3 0 (start nucleotide position 1959, Gene Bank accession number M83554) to yield an 840-base pair amplicon (Herszfeld et al., 2006) . Forty-five PCR cycles were performed and the annealing temperature was 608C. The cDNA from a Hodgkin disease tumour cell line (Gentaur Molecular Products; Brussel, Belgium) represented the positive control sample.
Relative quantitative real-time RT-PCR
Rq-RT -PCR was performed on the ABI 7500 real-time PCR system according to the manufacturer's protocol, using Assays on Demand gene expression products (Applera International Inc., Pleasanton, USA): CD30 (Hs01114495_m1), VIMENTIN (Hs00185584_m1), the POU class 5 homeobox 1 POU5F1 (Hs00742896_s1), teratocarcinoma-derived growth factor 1 TDGF-1 (Hs2339499_g1) and HCG b-subunit (Hs00361224_gH) (Applied Biosystems, Foster City, USA). For NANOG, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ubiquitin (UBQ) we have used assays of our own design and the sequences of the primers and probes are presented in Table I . Relative quantification of gene expression was achieved by normalization against the mean of endogenous controls GAPDH and UBQ using the DDCt method (Willems et al., 2006) . Fold changes were calculated as 2 2DDCt .
Immunocytochemistry
hESC colonies were fixed in 70% ethanol for 5 min and were incubated with mouse monoclonal antibody CD30 (clone Ber-H2, IgG; Dako, Glostrup, Denmark; dilution 1:67). Following overnight incubation, the cells were incubated with the Alexa fluor 488-conjugated F(ab 0 ) 2 fragments of goat anti-mouse immunoglobulin IgG (Molecular Probes, Eugene, OR, USA; dilution 1:200) for 2 h at 48C in the dark. Controls for antibody specificity included substitution with mouse IgG (Zymed, San Francisco, CA, USA; dilution 1:250).
For the CD30/VIMENTIN double immunostaining, incubation with the mouse primary antibody for CD30 was carried out at room temperature for 1 h, followed by incubation with the secondary antibody Alexa fluor 488-conjugated F(ab 0 ) 2 fragment of goat anti-mouse IgG (HþL) (1:200 dilution) for 1 h at room temperature. A final incubation was performed for 1 h with Alexa fluor 647-conjugated VIMENTIN antibody (clone V9, IgG; Santa Cruz, Santa Cruz, CA, USA; dilution 1:50).
For the CD30/NANOG double immunostaining, incubation with a mixture of mouse primary antibody for CD30 (IgG; Dako, dilution 1:67) and rabbit mouse antibody for NANOG (Abcam; Cambridge, MA, USA; dilution 1:50) was carried out overnight at 48C. The secondary antibody Alexa fluor 647-conjugated F(ab 0 ) 2 fragment of donkey anti-rabbit IgG (HþL) (Molecular Probes; dilution 1:200) was applied for 2 h at room temperature. A final incubation was performed with Alexa fluor 488-conjugated F(ab 0 ) 2 fragment of goat anti-mouse IgG (HþL) (dilution 1:200) for 1 h at room temperature.
Hoechst coloration was used for staining the nuclei. The images were taken with an Argon -Krypton laser (488/647) (Fluoview IX 200; Olympus, Aartselaar, Belgium) either using the CellF software program (Olympus) or scanned with the confocal unit of the microscope.
Fluorescence-activated cell sorting
To detect the cell surface antigens, hESC cells were washed in phosphatebuffered saline (PBS) and collected with Cell Dissociation Solution (Sigma). The cells were further incubated for 30 min at room temperature with 10 mg/ml monoclonal antibodies: mouse anti stage-specific embryonic antigen SSEA-1 (IgM; MAB4301, Millipore, Billerica, MA, USA), rat anti SSEA-3 (IgM; MAB4303, Millipore), mouse anti TRA-1-60 (IgM; MAB4360, Millipore), mouse anti TRA-1-81 (IgM; MAB4381, Millipore), mouse anti SSEA-4 (IgG, MAB4304, Millipore), and mouse anti CD30 (clone Ber-H2) (IgG; MO751, DAKO), washed with 1% human albumin and incubated with the secondary antibody Alexa fluor 488-conjugated F(ab 0 ) 2 fragments of goat anti-mouse immunoglobulins IgM or IgG, for 30 min at room temperature. For the CD9 staining, anti-human fluorescein labelled antibody (IgG, R&D Systems; Abingdon, UK) was used. The isotype control antibodies mouse IgM (Caltag, Carlsbad, CA, USA) and mouse IgG (Zymed) were used. Approximately 10 000 events were analysed per sample for each marker by FACS using the Coulter Epic XL-MCL (Analis, Ghent, Belgium).
Karyotyping
Array-CGH (aCGH) was performed using in-house arrays from the Microarray facility, VIB, K.U. Leuven, Belgium (www.microarrays.be). Genomic DNA was extracted from peripheral blood from male and female controls and used as references. aCGH was carried out as previously described (Spits et al., 2008) . The slides were scanned using an Agilent dual laser DNA microarray scanner G2566AA (Agilent Technologies, Palo Alto, CA, USA). The images were processed with Agilent Feature Extraction Software v9.5 and the final steps of data analysis were performed using Excel (Microsoft Corporation, Redmond, WA, USA). Small chromosomal aberrations, detected by aCGH in at least two consecutive passages, were confirmed by FISH using one or two of the bacterial artificial chromosomes/P1 artificial chromosomes located in the abnormality. The clones were labelled and the FISH was performed as described by Spits et al. (2008) . The nuclei were examined using an Axioplan 2 microscope (Zeiss, Zaventem, Belgium). FISH chromosome paints were carried out for chromosomes 5 and 18, on VUB04_CF as detailed in Spits et al. (2008) .
Genetic fingerprinting
Genomic DNA from VUB01 and VUB02 was extracted using the DNeasy tissue kit (Qiagen, Valencia, CA, USA) and the DNA fingerprinting was performed on the two cell lines using short tandem repeat loci: D22S423 (chromosome 22), D21S1413 (chromosome 21), D15S153 (chromosome 15) and AFM328yc5m (chromosome 14). For PCR, 30 cycles were performed: 1 min at 948C, 1 min at 608C, 1 min at 728C and a final extension for 7 min at 728C. Aliquots of 1 m1 of PCR product were mixed with 0.5 m1 of GeneScan-500 ROX (Applied Biosystems) size standard and 2.5 m1 of deionized formamide. The samples were then denatured at 958C for 2 -3 min and cooled in ice. Analysis was carried out on an ABI 3130 Genetic Analyzer (Applied Biosystems) for 2 h. Fragment sizes were determined automatically using Genescan software version 2.1 and compared with the allelic ladder by Genotyper software version 2.1 (both from Applied Biosystems).
Telomerase activity
Telomerase activity was measured in three independent assays in two hESC lines (VUB01 and VUB02) and in a lung cancer cell line ( CD30 in human embryonic stem cells in serum-free media to perform real-time PCR analysis using SYBER green I dye. Briefly, the hESC colonies were collected after 1/2 h of collagenase treatment, pelleted, washed once in PBS and stored at -808C. After thawing, extraction was carried out with Lysing Buffer containing protease inhibitor cocktail (Sigma). Each sample consisted of two assays: one with the extract and one with a heat-treated extract (858C for 10 min) representing the negative control. Ten microliter of cell extract is added to the QTD premix containing telomere primers. The real-time cycler steps were: telomerase reaction for 20 min at 258C, PCR initial activation step for 10 min at 958C and 3-step cycling with denaturation at 958C for 30 s, annealing at 608C for 30 s and extension at 728C for 30 s. Forty cycles were performed for each sample.
In vivo differentiation
The potential of VUB01 and VUB02 to differentiate into ectodermal, mesodermal and endodermal cells after prolonged culture was investigated in vivo through teratoma formation after xenografting in mice. Cells at P300 (VUB01) and P250 (VUB02) were injected i.m. into the rear leg muscle of 4-week-old male severely compromised immunodeficient beige mice. The resulting teratomas were excised 9 1/2 weeks posttransplantation, fixed in 4% neutral phosphate-buffered formalin, and embedded in paraffin. Hematoxylin-eosin (HE) staining was used to identify the presence of the three germ layers: endoderm, mesoderm and ectoderm.
Statistical analysis
Each experiment was repeated at least three times. The values presented are mean + SD. Differences between groups were determined by paired t-test. The x 2 -test was used to analyse the difference in the clonogenic capacity between the CD30 þ and CD30 2 populations of VUB01 with 46XY,dup(20)(q11.21) karyotype. A P-value of ,0.05 was considered significant.
Results
CD30 expression in VUB hESC lines
As an initial step to evaluate expression of CD30 in hESC derived and cultured in our laboratory, different hESC lines were screened by RT -PCR using the same primers as previously reported (Herszfeld et al., 2006) that identify the canonical form of CD30 transcripts. We have analysed hESC lines with normal karyotype (VUB07), with gross karyotype abnormalities (VUB13_FXS, 45,X,-X,dup(5)(q21.3qter), del(18)(q12.1qter)), and with submicroscopic (VUB01,46XY,dup(20) (q11.21)) changes (Spits et al., 2008) . The result depicted in Fig. 1A showed that hESC expressed CD30 transcript, irrespective of their chromosomal constitution. Subsequently, immunocytochemistry for CD30 using the Ber-H2 antibody showed a characteristic cell border staining, confirming the presence of CD30 at the protein level (Fig. 1B, C) . In addition, as our laboratory routinely derives hESC lines from preimplantation embryos, we had access to cells at P2 (28 days after inner cell mass was plated) of a newly derived line. hESC left attached to the MEF after mechanical passage of the colony were subjected to double immunostaining for CD30 and NANOG. The cells showed membrane-positive staining of CD30 indicating its early expression in hESC. The simultaneous expression of NANOG in the nuclei confirmed the pluripotent nature of the cells (Fig. 1D ). Once established, this cell line (VUB28_HD_MF) was fully characterized and was shown to have a 46,XX normal karyotype. In addition, immunostaining showed that cells cultured on MEF that presented morphological signs of early spontaneous differentiation were negative for CD30 (Fig. 1E) .
Correlation of CD30 expression with chromosomal aberrations
To better estimate the effect of different chromosomal constitutions on CD30 expression, we performed FACS and Rq RT-PCR for characterizing both the cell surface protein expression and mRNA levels of CD30 on cells with different karyotypes. In order to avoid the inherent differences between hESC lines, two lines that presented a normal karyotype, as tested by aCGH at early passages, were compared with their respective later passages, when the lines had acquired chromosomal aberrations (Table II) . VUB02 was evaluated at P66 (46,XY) and at P269 when it showed a submicroscopic chromosomal abnormality (46,XY,dup (20)(q11.21)). VUB04_CF was evaluated at P23 (46,XX) and 136 when it showed gross karyotype changes (46,XX, dup(5)(q14.2qter),del(18)(q21.2qter)) (Fig. 2) . Three independent cultures were evaluated for each passage of each sample.
Aiming for an evaluation of CD30 in undifferentiated hESC, and taking into account the down-regulation of CD30 during spontaneous differentiation, CD30 expression was compared with the expression of cell surface markers characteristic of undifferentiated (SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 and CD9) and differentiated (SSEA-1) hESC when analysed by FACS. By the same reasoning, for gene expression studies by Rq-RT-PCR the results for CD30 transcripts were correlated with the expression of three genes (NANOG, POU5F1, TDGF-1) which are considered as the archetypal 'stemness' markers (defining undifferentiated hESCs) and with expression of b-hCG subunit, associated with trophectoderm differentiation (ISCI, 2007) .
The FACS results for VUB02 showed that cells with abnormal and normal chromosomal constitution were strongly positive for CD30, with no difference in percentage of positive cells between the two cell types (mean values 95.4 versus 96.7%, respectively) (Fig. 3A) . Regarding the data for VUB04_CF, aneuploid cells showed a weak positivity for CD30, with a significantly lower proportion of CD30 þ cells when compared with euploid cells (mean values 67.8 versus 96.5%; P ¼ 0.006) (Fig. 3A) . No differences were observed in the expression of SSEA-1 or of SSEA-4, TRA-1-60, TRA-1-81 and CD9 between euploid and aneuploid variants of both lines, but SSEA-3 expression differed (mean values 92.8 versus 72.7%; P ¼ 0.048) in case of VUB02 (Fig. 3A) . In addition, the high percentage of cells positive for the markers of undifferentiated cells and the very low proportion of SSEA-1 þ cells indicated that nearly all the cells analysed from both VUB02 and VUB04_CF cultures were undifferentiated. The Rq RT-PCR analysis confirmed the FACS results by showing a significantly lower expression of CD30 (c. 3.5 mean fold; P ¼ 0.045) in aneuploid versus euploid cells of VUB04_CF (Fig. 3B) . No significant difference in CD30 expression between cells with normal and abnormal chromosomal constitution was observed in VUB02, although a slight tendency (c. 1.5 mean fold) to a higher expression in the abnormal cells was observed (Fig. 3B) . The Rq RT -PCR analysis of the other hESC markers showed no significant differences between chromosomally normal and abnormal cells in both lines.
In addition to VUB02 and VUB04_CF lines, two different sublines of a third line, VUB01, that presented different chromosomal abnormalities were evaluated at P71 (45,XY,-18) and P334 (mosaic 46,XY and 46,XY,dup(20)(q11.21)) (Fig. 2) ; this late passage presented a similar chromosomal abnormality as VUB02 but, in contrast to the duplication in VUB02, here the duplication includes the DNMT3B gene. Unfortunately, no material from VUB01 with normal karyotype was available at the time of these experiments.
FACS analysis showed high expression of SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, CD9 and low expression of SSEA-1 indicating an undifferentiated status of the VUB01 cells analysed. In addition, no difference with respect to these markers was observed between VUB01 cells with different chromosomal constitutions (Fig. 4A) . Regarding the CD30 marker, although cells at P71 (45,XY,-18) were strongly positive (mean value 97.7%), two distinct populations, CD30
2 and CD30 þ (mean value 60.5%), were observed at P334 (46,XY,dup(20)(q11.21)) (Fig. 4C, D) . Immunocytochemistry for CD30 on VUB01 with the dup(20)(q11.21) abnormality showed absence of expression in some of the hESC colonies (Fig. 4E) . The Rq RT-PCR confirmed down-regulation of CD30 expression at the mRNA level in the cells from P334 with the dup(20)(q11.21) when compared with the cells from P71 with the monosomy 18 (c.3 mean fold; P ¼ 0.004) (Fig. 4B) . Taken together, these data indicate no correlation of CD30 expression with chromosomal abnormalities, either gross or submicroscopic, both at protein and mRNA levels. However, the presence of (Fig. 4F, G ).
CD30 expression during early spontaneous differentiation of hESC
To evaluate the expression of CD30 in conditions that favours spontaneous differentiation, karyotypically normal hESC (VUB02, P60 and VUB04_CF, P25) were plated on matrigel TM in hESC medium and cultured further for 4 days. These conditions allow the appearance of mesenchymal-like cells at the periphery of the colonies. Double immunocytochemistry was performed at day 1, 2 and 4 for CD30 and VIMENTIN. VIMENTIN belongs to the intermediate filament family that is highly expressed in mesenchymal cells and has been used as a specific mesenchymal marker for the characterization of the epithelial-to-mesenchymal transition (EMT) in hESC (Ullmann et al., 2007) .
At day 1 after plating, VIMENTIN staining was restricted to the border of the colony (Fig. 5A ). In the following days, as described before (Ullmann et al., 2007) , more VIMENTIN positive cells were observed as the differentiation progressed towards a mesenchymallike phenotype (Fig. 5B) . On the other hand, fewer CD30 positive cells were present at day 4 when most of the cells were differentiated (Fig. 5C ).
To confirm these results, Rq RT -PCR was performed for CD30, VIMENTIN, and for the stemness markers POU5F1 and NANOG transcripts on RNA samples collected at day 2 and 4. Expression of POU5F1 and NANOG was down-regulated while VIMENTIN was strongly up-regulated versus undifferentiated cells, indicating differentiation by day 2 and 4. CD30 mRNA was down-regulated in the same manner as POU5F1 and NANOG indicating the loss of CD30 expression at RNA level during early spontaneous differentiation, confirming the immunostaining results (Fig. 5D ).
Correlation of CD30 expression with culture media
Owing to the presence of CD30 in all our hESC lines, we took into account the possibility that the CD30 expression may be related to culture conditions, especially hESC medium, and, if so, we raised the question of whether hESC medium could induce the expression of CD30 in cells other than hESC. Therefore, HF were cultured for 14 days in hESC medium and analysed for the presence of CD30 transcripts. Rq RT-PCR results revealed that HF cultured for 7 and 14 days in hESC medium display a significantly increased expression of CD30 transcripts, of 4.6 (d7; P ¼ 0.04) and 34.4 (d14; P ¼ 0.01) fold, when compared with HF cultured in parallel in MEF medium (Fig. 6A ). These results suggest a possible role of hESC medium in inducing CD30 expression. Consequently, in the next step we were interested to test two other media used to culture hESC: hESC medium containing FBS instead of KO -SR, and the commercially available mTeSR medium. For this, expression of CD30 transcripts was evaluated in VUB01 (P72), VUB02 (P66) and VUB04_CF (P26) cultured for one passage in either of the two media, and compared with cells cultured in hESC medium containing KO -SR. The Rq RT -PCR results indicated a tendency towards an increased expression of CD30 transcripts in mTeSR medium and a slight decrease in case of FBS-containing medium as compared with the standard KO-SR containing medium (Fig. 6B) . Immunostaining for CD30 revealed a more intense positive expression in hESC cultured in mTeSR medium than in FBS-containing medium (Fig. 6C, D) .
Clonogenic capacity of CD30
1 hESC
To determine whether the presence of CD30 offers growth advantage to the cultured cells, we have tested the clonogenic capacity of the CD30 þ and CD30 2 sorted populations of two independent cultures of VUB01 at P340 (46,XY,dup (20)(q11.21)). For clonogenic capacity, 10 000 cells from each population were plated on MEF and cultured for 10 days in hESC medium. The cloning efficiency was low (,0.5%) in both samples but a significantly higher capacity to re-initiate cultures was observed in the CD30 þ population (mean values 0.275 versus 0.06%, P , 0.001) (Fig. 7A) . No difference in the morphological appearance of the colonies from both samples was observed. Immunostaining confirms the positive and the negative CD30 expression in the colonies resulting from CD30 þ to CD30 2 sorted cells, respectively (Fig. 7B, C) .
Characterization of long-term culture of VUB01 and VUB02
VUB01 was continuously cultured for almost 5 years, and VUB02 was frozen at P10, thawed and then continuously cultured for 4 years. In order to rule out any possible contamination between the hESC lines, markers on four different chromosomes were analysed using genetic fingerprinting. The results showed the absence of any contamination between the two cell lines under study (Fig. 8A) .
hESC from VUB01 and VUB02 showed high levels of telomerase activity (comparable to a human tumour cell line used as a positive control) in both early (P66 and P34 in VUB01 and VUB02, respectively) and late (P258 and P218 in VUB01 and VUB02, respectively) passages, as determined by Rq RT -PCR, indicating no sign of senescence with continuous culture (Fig. 7B) . Finally, the potential of VUB01 and VUB02 to differentiate after prolonged culture (P300 and P250, respectively) was investigated. HE staining identified the presence of all three germ layers (endoderm, ectoderm and mesoderm) in teratomas from immunocompromised mice indicating the pluripotent capacity of both hESC lines at very late passages (Fig. 8C-F) .
Discussion
This investigation reports on the expression of CD30 in undifferentiated hESC derived and cultured in our laboratory, with normal or abnormal chromosomal constitution as demonstrated by aCGH.
Expression of CD30 during spontaneous differentiation of hESC was also evaluated. Our results are based on analysis at mRNA and protein level and apparently contradict, at least partly, previously reported results (Herszfeld et al., 2006; Thomson et al., 2008) .
In our laboratory, hESC are cultured in serum-free medium on feeder layers and passaged by mechanical means. In these conditions, we reported genetic instability of hESC lines, including submicroscopic duplications, mainly at 20q11.21, the recurrent appearance of a derivative chromosome 18, and monosomies or triploidies (Spits et al., 2008) . Herszfeld et al. (2006) reported expression of CD30 only in chromosomally abnormal cell lines, indicating a possible use of CD30 as a biomarker for transformed cell lines. We show here that undifferentiated hESC with normal genetic constitution can be highly positive for CD30 and can express CD30 transcripts, even at very early passages. Cells with abnormalities representative of all the different types of chromosomal changes reported in our laboratory also showed expression of CD30. When comparing normal and abnormal sublines of the same hESC line, no correlation of CD30 expression with the chromosomal constitution was observed. Although VUB04_CF carrying derivative chromosome 18 (46,XX, Figure 5 Characterization of CD30 expression during early spontaneous differentiation of hESC lines. Double immunostaining for CD30 and VIMENTIN during spontaneous differentiation of hESC cultured for 4 days on matrigel TM in hESCmedium at day 1 (A), day 2 (B) and day 4 (C). Inserts represent nuclear staining with Hoechst. Scale bar 50 mm. (D) Rq-RT -PCR of NANOG, POU5F1, CD30 and VIMENTIN in mRNA samples collected at day 2 (d2) and d4 after VUB02 cells were plated on matrigel TM and cultured in hESC medium. mRNA levels were compared with the respective undifferentiated cells, considered as having value 1 (Y-axis) and significant differences are indicated (*P , 0.05). Data are mean + SD of three independent PCRs. The experiment was repeated on VUB01 and VUB04_CF.
dup (5) We have also shown that the expression of CD30 is rapidly lost during spontaneous differentiation of hESC, as tested in an EMT system. The presence of CD30 in all our hESC from very early passages, as shown in VUB28_HD_MF line, leads to the hypothesis that the CD30 expression in hESC lines is not a consequence of chromosomal abnormalities, but rather of the culture conditions. This hypothesis is supported by the results showing that human fibroblasts negative for CD30 up-regulate the expression of CD30 transcripts when cultured for 2 weeks in serum-free medium (KO -SR-containing hESC medium), therefore indicating the hESC medium, and most probably the KO-SR, as a candidate responsible for inducing CD30 expression in hESC. This idea is supported by the tendency of chromosomally normal hESC cultured in KO-SR-containing medium to down-regulate CD30 expression when switched for one passage to a medium containing serum, and to up-regulate expression when cultured on matrigel TM in mTeSR medium containing human albumin.
However, Herszfeld et al. (2006) did not consider the possibility that CD30 expression is related to the presence of certain components in the KO-SR, or conversely to the absence of serum, taking into account that in their hands diploid cultures grown for as many as 20 passages in the serum-free medium were negative for CD30 transcripts or surface staining. Nevertheless, while this manuscript was in preparation, Chung et al. (2008) reported that components of KO-SR are responsible for the induction of CD30 expression in hESC by demethylation of CpG islands in the CD30 promoter. This report is in concordance with our hypothesis that culture conditions, and especially KO-SR, are involved in the expression of CD30 in hESC. Chung et al. (2008) also mention that the CD30 expression is induced in hESC prior to the detection of any karyotype abnormalities, but our results do not support this conclusion.
In another study (Thomson et al., 2008) , hESC cultured on matrigel TM with KO-SR-containing medium previously conditioned by inactivated MEF, expressed CD30 in cells with either normal or abnormal karyotype. Although similar, our results do not confirm the presence of a higher proportion of CD30 þ cells in the abnormal
cultures. An explanation might be the different culture conditions: matrigel TM instead of feeder layers, and enzymatic passage instead of the mechanical approach. In our experience, the culture conditions used by Thomson et al. (2008) enhance the EMT, thereby increasing the presence of differentiated hESC when compared with culture on feeders (Ullmann et al., 2007) . It was not clear from the Thomson et al. (2008) report if the samples analysed by FACS for CD30 expression were also evaluated for cell-surface markers of undifferentiated hESC cells (SSEA-3, SSEA-4; TRA-1-60, TRA-1-81). Taking into account that CD30 expression is down-regulated during in-vitro differentiation as we have shown in the present report, it might be possible that the lower expression in the sample with normal karyotype reported by Thomson et al. (2008) is a consequence of a higher differentiation rate compared with the samples with abnormal karyotype.
The biological function of CD30 in hESC is still unknown, although its involvement in protecting hESC against apoptosis was previously reported (Herszfeld et al., 2006) . We have also shown that CD30 þ hESC have an increased capacity to reinitiate cultures from single cells, most likely a consequence of decreased apoptosis that provides a survival advantage. As mentioned above, Chung et al. (2008) reported that KO-SR-containing medium induces CD30 expression prior to the detection of any karyotypic abnormalities, and concluded that CD30 confers a selective advantage for hESC through protecting against apoptosis, thus enhancing the risk for genetic instability through diminished culling of cells with newly acquired chromosomal abnormalities. Although their findings confirm ours regarding the effect of KO -SR on CD30 expression, we were not able to confirm that CD30 is causally linked to the emergence of karyotypic abnormalities. Nevertheless, this observation may explain the expression of CD30 in karyotypically normal hESC even at very early passages, as well as the presence of karyotypic abnormalities in our cell lines. This hypothesis also reconciles our results with those of Herszfeld et al. (2006) who correlated CD30 expression with karyotypic abnormalities without establishing the exact chain of causative events.
The role of CD30 in the genetic (in)stability and transformation of hESC was also supported by Grandela and Wolvetang (2007) . Preliminary data from their laboratory suggest that signalling downstream of CD30 may affect the expression of genes involved in genetic stability and chromosome segregation. Their results showed that CD30 þ hESC show a reduced expression of p53 (mediator of apoptosis) and an increased expression of SURVIVIN (inhibitor of apoptosis). Gene expression analysis, as well as the quantification of apoptosis in the two distinct CD30 populations in VUB01, would give more in depth information about the function of CD30 in hESC, and probably would help to explain the presence of CD30 2 cells in some lines (VUB01 and VUB04_CF). These studies will be the subject of further investigations as the aim of the present report was focused on the possible correlation between CD30 expression and chromosomal abnormalities in hESC lines using our culture conditions. Another interesting line of research would be the investigation of CD30 expression in human embryos obtained after IVF. The medium used to culture embryos from day 2 (4-8 cell stage) through to day 5 (blastocyst stage) (BlastAssist; MediCult, www.medicult.com; Denmark) contains synthetic serum replacement of a different commercial origin to that of KO-SR. Considering the presence of CD30 in very early passages of hESC cultured in serumfree medium and the possible effect of KO-SR on genomic stability in hESC, it would be interesting to assess CD30 expression at different stages of embryo development and to correlate the results with the (epi)genetic and apoptotic status of the embryo.
In our experiments on the evaluation of CD30 in undifferentiated hESC, attention was paid to avoiding the collection of differentiated cells. Moreover, each sample analysed for CD30 was also evaluated, both by FACS and Rq RT-PCR, for the expression of markers that define the undifferentiated state of hESC. Therefore, by analysing two different lines (VUB02 and VUB04_CF) at early and late passages with normal and abnormal chromosomal constitution, respectively, we were able to point out that expression of markers characteristic of stem cells does not change in undifferentiated cells during long-term culture or when cells acquire chromosomal abnormalities, gross or submicroscopic. One exception is SSEA-3 which showed lower expression in the late passages that carry chromosomal abnormalities, as observed in VUB02. However, this does not seem to be the case for all the lines, as exemplified by VUB01 carrying either the monosomy 18 (45,XY,-18) or the duplication 20q11.21: VUB01 presents a high number of SSEA-3 þ cells, comparable with the early normal passages of VUB02 and VUB04_CF.
In conclusion, the presence of CD30 transcript and protein in all hESC lines independent of their chromosomal constitution, even from early passages, and its down-regulation during the early spontaneous differentiation indicate that CD30 behaves more as a marker of undifferentiated hESC than of transformed cells, at least when cultured in serum-free media. We have also indicated a possible role for KO-SR in inducing CD30 expression in hESC, most probably through epigenetic activation as postulated by Chung et al. (2008) . As CD30 is highly expressed in embryonal carcinomas and some lymphomas but absent from most adult and embryonic tissue, its expression in hESC cultured in serum-free medium is of great concern for further use of hESC in different applications. Investigation of the events that trigger its expression in hESC is therefore necessary for developing culture systems that will allow expansion of the hESC without undesired characteristics, such as chromosomal aberrations. Furthermore, although a possible role in apoptosis and genetic instability have been reported, more studies to elucidate the molecular pathways downstream of CD30 in hESC are required.
Finally, we provide evidence that the presence of chromosomal abnormalities or long-term culture of hESC do not influence the expression of stem cell markers in undifferentiated hESC cells.
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